The below information on Omniscan has been taken from official FDA sources, but we cannot guarantee it's accuracy. Please use this site for educational purposes only. This site does not replace a proper discussion with your doctor.
|This drug was approved by the FDA in one form or another on:|
|This drug is made in one form or another by the following companies:|
|This drug is available in the following forms:|
|View the actual FDA approved label for this drug at the following links:|
Omniscan (gadodiamide) Injection is the formulation of the gadolinium complex of diethylenetriamine pentaacetic acid bismethylamide, and is an injectable, nonionic extracellular enhancing agent for magnetic resonance imaging. Omniscan is to be administered by intravenous injection.
Precautions for Omniscan
Some paramagnetic contrast agents may impair the visualization of existing lesions which are seen on the unenhanced, noncontrast MRI. This may be due to effects of the paramagnetic contrast agent, imaging parameters, misregistration, etc. CAUTION SHOULD BE EXERCISED WHEN A CONTRAST ENHANCED INTERPRETATION IS MADE IN THE ABSENCE OF A COMPANION UNENHANCED MRI.
Omniscan is cleared from the body by glomerular filtration. Significant hepatobiliary enteric pathway excretion has not been demonstrated. Dose adjustments in renal or hepatic impairment have not been studied. Caution should be exercised in patients with impaired renal insufficiency with or without hepatic impairment. For elimination of Omniscan in pediatric patients.
The possibility of a reaction, including serious, life threatening, fatal, anaphylactoid or cardiovascular reactions or other idiosyncratic reactions should always be considered especially in those patients with a known clinical hypersensitivity, a history of asthma, or other allergic respiratory disorders.
Repeat procedures: Sequential use during the same diagnostic session has been studied in adult central nervous system use only. Data for sequential injections during the same session or repeated injections for monitoring in other indications are not available. If the physician determines repeat dosing is required in non-CNS use in adults or in CNS pediatric administration, in patients with normal renal function the time interval between repeat doses should be at least 7 hours to allow for normal clearance of the drug from the body.
Omniscan should be drawn into the syringe and used immediately. If nondisposable equipment is used, scrupulous care should be taken to prevent residual contamination with traces of cleansing agents.
Diagnostic procedures involving the use of contrast agents should be conducted under supervision of a physician with the prerequisite training and a thorough knowledge of the procedure to be performed.
Recent Forum Posts on Omniscan
Site Copyright © 2003-2008 Jalic Inc. All rights reserved.